A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
University of Michigan
University of Michigan Comprehensive Cancer Center
Principal Investigator
Tejas Patil, MD
Study ID
Protocol Number: 22-1450
More information available at ClinicalTrials.gov: NCT05845671
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers